It appears that Sanofi’s loss is Shionogi’s gain. Five months after the Federal Trade Commission (FTC) scuttled Sanofi’s ...

MacroGenics’ safety woes have followed it into phase 2. Having dialed down the dose in response to early-phase data, the ...

The FDA is alerting users and providers to Tandem Diabetes Care’s recall of its insulin pump-controlling iPhone app, after a ...

Innovent has scored another phase 3 win for mazdutide as the drug showed its superiority to Eli Lilly's diabetes and heart ...

The need to stretch strained bank balances has hit pipelines once again. | The need to stretch strained bank balances has hit ...

The U.S. FDA, the Environmental Protection Agency and the Department of Agriculture have answered the Biden administration’s ...

Following 12 company recalls and nearly 3,000 reported issues related to its cardiovascular life support systems since January 2023, Getinge has now drawn more scrutiny from the FDA — as the agency ...

In its ongoing mission to find the next Wegovy, Novo Nordisk has penned another partnership to seek out next-gen obesity ...

Phil Gregory’s new gig looks a whole lot like his old gig. It’s just that, under the umbrella of Regeneron, things have ...

Ring Therapeutics revealed data at the 2024 American Society for Gene and Cell Therapy meeting showing that a viral vector ...

Conversations about clinical trial diversity have finally gone mainstream, but | Sponsors have struggled to improve diversity ...

Takeda has made some cuts to its clinical-phase pipeline, hacking off midphase programs and early-stage prospects as part of a push to focus on its most promising candidates.  | Takeda has taken an ax ...